STOCK TITAN

Fusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2021, at 11:00am EDT. The CEO, John Valliant, Ph.D., will represent the company. A live webcast will be available on the company’s website and will be archived for 30 days post-event. Fusion specializes in developing next-generation radiopharmaceuticals, including its lead program, FPI-1434, currently in Phase 1 clinical trials. The company employs proprietary technology to deliver alpha particles selectively to tumors.

Positive
  • None.
Negative
  • None.

HAMILTON, ON and BOSTON, May 27, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 11:00am EDT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.  

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform which includes internal research and development capabilities, manufacturing and supply chain expertise, and the Company's proprietary Fast-Clear™ linker technology.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-301301052.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

When will Fusion Pharmaceuticals present at the Jefferies Virtual Healthcare Conference?

Fusion Pharmaceuticals will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 11:00am EDT.

Who will represent Fusion Pharmaceuticals during the presentation?

CEO John Valliant, Ph.D., will represent Fusion Pharmaceuticals during the presentation.

How can I listen to the webcast of the Fusion Pharmaceuticals presentation?

The live webcast will be available on the 'Events and Presentations' page of Fusion's website.

What is the focus of Fusion Pharmaceuticals?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals as precision medicines for oncology.

What is Fusion Pharmaceuticals' lead program?

Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

Fusion Pharmaceuticals Inc. Common Shares

NASDAQ:FUSN

FUSN Rankings

FUSN Latest News

FUSN Stock Data

1.83B
75.27M
0.47%
86.8%
3.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
HAMILTON